Representative Josh Gottheimer (D-New Jersey) recently sold shares of Roche Holding AG (OTCMKTS:RHHBY). In a filing disclosed on May 14th, the Representative disclosed that they had sold between $1,001 and $15,000 in Roche stock on April 9th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account.
Representative Josh Gottheimer also recently made the following trade(s):
- Purchased $1,001 – $15,000 in shares of RTX (NYSE:RTX) on 4/23/2025.
- Purchased $1,001 – $15,000 in shares of Cheniere Energy (NYSE:LNG) on 4/22/2025.
- Purchased $1,001 – $15,000 in shares of Techtronic Industries (OTCMKTS:TTNDY) on 4/21/2025.
- Purchased $1,001 – $15,000 in shares of Tri Pointe Homes (NYSE:TPH) on 4/21/2025.
- Purchased $1,001 – $15,000 in shares of Perusahaan Perseroan (Persero) PT Telekomunikasi Indonesia Tbk (NYSE:TLK) on 4/21/2025.
- Sold $1,001 – $15,000 in shares of KKR & Co. Inc. (NYSE:KKR) on 4/21/2025.
- Purchased $1,001 – $15,000 in shares of D.R. Horton (NYSE:DHI) on 4/21/2025.
- Purchased $1,001 – $15,000 in shares of Home Depot (NYSE:HD) on 4/21/2025.
- Sold $1,001 – $15,000 in shares of Hillman Solutions (NASDAQ:HLMN) on 4/17/2025.
- Sold $1,001 – $15,000 in shares of AbbVie (NYSE:ABBV) on 4/17/2025.
Roche Stock Performance
Shares of RHHBY stock opened at $38.40 on Friday. The company has a current ratio of 1.26, a quick ratio of 0.97 and a debt-to-equity ratio of 0.86. Roche Holding AG has a fifty-two week low of $31.19 and a fifty-two week high of $44.31. The stock has a 50 day moving average price of $40.10 and a two-hundred day moving average price of $38.60.
Institutional Investors Weigh In On Roche
Analysts Set New Price Targets
A number of brokerages recently commented on RHHBY. HSBC downgraded Roche from a “buy” rating to a “hold” rating in a report on Monday, April 28th. UBS Group upgraded Roche from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Sanford C. Bernstein raised Roche to a “strong-buy” rating in a research note on Thursday, January 30th. Morgan Stanley assumed coverage on Roche in a research note on Wednesday, February 12th. They issued an “equal weight” rating on the stock. Finally, Hsbc Global Res cut Roche from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 28th. Two research analysts have rated the stock with a sell rating, three have given a hold rating, one has assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold”.
View Our Latest Stock Report on RHHBY
About Representative Gottheimer
Josh Gottheimer (Democratic Party) is a member of the U.S. House, representing New Jersey’s 5th Congressional District. He assumed office on January 3, 2017. His current term ends on January 3, 2027.
Gottheimer (Democratic Party) is running for re-election to the U.S. House to represent New Jersey’s 5th Congressional District. He declared candidacy for the 2026 election.
Gottheimer is also running for election for Governor of New Jersey. He declared candidacy for the Democratic primary scheduled on June 10, 2025.
Gottheimer attended the University of Pennsylvania for his undergraduate degree. He became a Thouron Fellow at Oxford and attended Harvard Law School. Gottheimer worked as a speech writer under former President Bill Clinton (D), assisting with two State of the Union addresses, among other projects. Before running for Congress, he worked for Microsoft as a general manager for corporate strategy.
About Roche
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.
Featured Articles
- Five stocks we like better than Roche
- Are Penny Stocks a Good Fit for Your Portfolio?
- Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades
- Energy and Oil Stocks Explained
- Symbotic Gets Big Earnings Lift: Is the Stock Investable Again?
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- 3 Small-Cap Stocks With Room to Run Despite Tariff Headwinds
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.